Medrossiprogesterone [Dcit] en es it fr

Medrossiprogesterone [Dcit] Brand names, Medrossiprogesterone [Dcit] Analogs

Medrossiprogesterone [Dcit] Brand Names Mixture

  • Lunelle (Medroxyprogesterone + Estradiol)

Medrossiprogesterone [Dcit] Chemical_Formula


Medrossiprogesterone [Dcit] RX_link

Medrossiprogesterone [Dcit] fda sheet

Medrossiprogesterone_[Dcit] FDA

Medrossiprogesterone [Dcit] msds (material safety sheet)

Medrossiprogesterone [Dcit] Synthesis Reference

P. Ruggieri, C. Ferrari, U.S. Pat. 3,043,832 (1962)

Medrossiprogesterone [Dcit] Molecular Weight

344.488 g/mol

Medrossiprogesterone [Dcit] Melting Point

220 - 223.5 oC

Medrossiprogesterone [Dcit] H2O Solubility


Medrossiprogesterone [Dcit] State


Medrossiprogesterone [Dcit] LogP


Medrossiprogesterone [Dcit] Dosage Forms

Tablets; Depo injection

Medrossiprogesterone [Dcit] Indication

Used as a contraceptive and to treat amenorrhea, abnormal uterine bleeding, endometriosis, endometrial and renal cell carcinomas, and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), Pickwickian syndrome, and other hypercapnic pulmonary conditions.

Medrossiprogesterone [Dcit] Pharmacology

Medroxyprogesterone is a synthetic progestin more potent than progesterone.

Medrossiprogesterone [Dcit] Absorption

Rapidly absorbed from GI tract

Medrossiprogesterone [Dcit] side effects and Toxicity

Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.

Medrossiprogesterone [Dcit] Patient Information

Medrossiprogesterone [Dcit] Organisms Affected

Humans and other mammals